{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"66"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.","groups":[{"description":"Participants with Ewing sarcoma received lenvatinib 14 mg/m\\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.","id":"OG000","title":"Ewing Sarcoma"},{"description":"Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Participants with high grade glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG002","title":"High Grade Glioma"},{"description":"Participants with diffuse midline glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG003","title":"Diffuse Midline Glioma"},{"description":"Participants with medulloblastoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG004","title":"Medulloblastoma"},{"description":"Participants with ependymoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG005","title":"Ependymoma"},{"description":"Participants with other solid tumors received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG006","title":"Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 50 months","title":"Number of Participants Who Experienced an Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}